CompletedPhase 3

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

United States1,315 participantsStarted 2009-03

Plain-language summary

The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female 18 to 80 years of age; * Previously met the preliminary criteria of American Rheumatism Associatio (ARA) for the classification of acute gout arthritis of primary gout; * Subjects with history of gout, initiating or currently on urate lowering; therapy who are at risk of gout flare. Exclusion Criteria: * Acute gout flare within 2 weeks prior to the screening visit and during the screening visit; * Persistent chronic or active infections; * History of an allergic reaction to allopurinol; * History or presence of cancer within 5 years of the Screening Visit;;;

What they're measuring

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

Timeframe: Baseline up to Week 20

Trial details

NCT IDNCT00856206

SponsorRegeneron Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2011-01

Results submitted2017-03-20

View on ClinicalTrials.gov More Gout trials